Dr. Lorraine Kalia’s research looks at testing different compounds in C. Elegans and how it can lead to a better understanding of Parkinson’s disease and new therapeutic targets. The best part: some of these compounds are already approved for use in humans. Through Dr. Kalia’s research we may be able to repurpose these compounds for the neurodegenerative condition.